Clinical Trials
154 trialsNCT02231749 2026-05-27
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Bristol-Myers Squibb
Phase 3 Completed
NCT04720157 2026-05-27
PSMAddition
Novartis
Phase 3 Active not recruiting
NCT05939414 2026-05-27
PSMA-DC
Novartis
Phase 3 Recruiting
NCT06120491 2026-05-27
EvoPAR-PR01
AstraZeneca
Phase 3 Active not recruiting
NCT06136650 2026-05-27
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06520345 2026-05-27
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT06524544 2026-05-27
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT03582774 2026-05-26
PSMA SRT
Jonsson Comprehensive Cancer Center
Phase 3 Active not recruiting
NCT05943106 2026-05-26
PATAPSCO
AstraZeneca
Phase 3 Active not recruiting
NCT07405164 2026-05-26
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07489495 2026-05-26
LITESPARK-034
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT01224288 2026-05-22
Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
NCT02106572 2026-05-22
TIM
Abnoba Gmbh
Phase 3 Terminated
NCT02799706 2026-05-22
PEGASUS
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Active not recruiting
NCT03260894 2026-05-22
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
Phase 3 Completed
NCT05043090 2026-05-22
SAMETA
AstraZeneca
Phase 3 Active not recruiting
NCT06510374 2026-05-22
ABLE-32
Ferring Pharmaceuticals
Phase 3 Recruiting
NCT06545955 2026-05-22
ABLE-22
Ferring Pharmaceuticals
Phase 3 Recruiting
NCT06925737 2026-05-22
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06986083 2026-05-22
A Study of Changes to Prostate Procedures
Memorial Sloan Kettering Cancer Center
Phase 3 Recruiting
NCT07028853 2026-05-22
MEVPRO-3
Pfizer
Phase 3 Recruiting
NCT07213674 2026-05-22
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Amgen
Phase 3 Recruiting
NCT07218380 2026-05-22
FORAGER-2
Eli Lilly and Company
Phase 3 Recruiting
NCT07419295 2026-05-22
TroFuse-031
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07427043 2026-05-22
ROPES
Brigham and Women's Hospital
Phase 3 Recruiting
NCT03274687 2026-05-20
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
NRG Oncology
Phase 3 Completed
NCT03987386 2026-05-20
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
NCT04588246 2026-05-20
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
Phase 3 Terminated
NCT06274047 2026-05-20
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
M.D. Anderson Cancer Center
Phase 3 Recruiting
NCT06629779 2026-05-20
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Pfizer
Phase 3 Recruiting
NCT07598032 2026-05-20
iCCaRE
University of Ilorin Teaching Hospital
Phase 3 Not yet recruiting
NCT05794906 2026-05-19
ARASTEP
Bayer
Phase 3 Active not recruiting
NCT06952803 2026-05-19
EvoPAR-PR02
AstraZeneca
Phase 3 Recruiting
NCT07477626 2026-05-19
RADVAN
Sun Yat-sen University
Phase 3 Active not recruiting
NCT07551544 2026-05-19
ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer
ImmunityBio, Inc.
Phase 3 Withdrawn
NCT04423211 2026-05-15
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT05239728 2026-05-15
MK-6482-022
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT06691984 2026-05-15
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Amgen
Phase 3 Active not recruiting
NCT07591467 2026-05-15
CaBRA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Not yet recruiting
NCT03574571 2026-05-14
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 3 Active not recruiting
NCT04195750 2026-05-14
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT06056830 2026-05-14
CLARIFY
Clarity Pharmaceuticals Ltd
Phase 3 Recruiting
NCT06970847 2026-05-14
AMPLIFY
Clarity Pharmaceuticals Ltd
Phase 3 Active not recruiting
NCT07011719 2026-05-14
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.
Phase 3 Recruiting
NCT03793166 2026-05-13
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04579224 2026-05-13
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05092958 2026-05-13
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT07227402 2026-05-12
LITESPARK-033
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT01946204 2026-05-11
SPARTAN
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT02257736 2026-05-11
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting